Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis

International Journal of Pharmaceutics

Volumn 345, Issue 1-2, 2007, Pages 154-162

  Kisich, K O ^a   Gelperina, S ^b   Higgins, M P ^a   Wilson, S ^a   Shipulo, E ^b   Oganesyan, E ^b   Heifets, L ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b Russian Research Center of Molecular Diagnostics and Therapy   (Russian Federation)

Author keywords

M. tuberculosis; Macrophage; Moxifloxacin; Nanoparticles; Poly(butyl cyanoacrylate)

Indexed keywords

ENBUCRILATE; MOXIFLOXACIN; NANOPARTICLE; POLY(BUTYLCYANOACRYLATE); POLYMER; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; BACTERIAL CELL; BACTERIAL GROWTH; CONCENTRATION (PARAMETERS); CYTOPLASM; DRUG EFFICACY; HUMAN; HUMAN CELL; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; AZA COMPOUNDS; BACILLUS SUBTILIS; BIOLOGICAL ASSAY; CELLS, CULTURED; DRUG COMPOUNDING; ENBUCRILATE; HUMANS; MACROPHAGES; MYCOBACTERIUM TUBERCULOSIS; NANOPARTICLES; PARTICLE SIZE; QUINOLINES; RHODAMINES; SUSPENSIONS;

EID: 36048983390     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.05.062     Document Type: Article

References (28)

1. Albermann N., Schmitz-Winnenthal F.H., Z'Graggen K., Volk C., Hoffmann M.M., Haefeli W.E., and Weiss L. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem. Pharmacol. 70 (2005) 949-958
2. Bakker-Woudenberg L.A., Schiffelers R.M., Storm G., Becker M.J., and Guo L. Long-circulating sterically stabilized liposomes in the treatment of infections. Methods Enzymol. 391 (2005) 228-260
3. Barrow W.W. Microsphere technology for chemotherapy of mycobacterial infections. Curr. Pharm. Des. 10 (2004) 3275-3284
4. Behan N., Birkinshaw C., and Clarke N. Poly n-butyl cyanoacrylate nanoparticles: a mechanistic study of polymerisation and particle formation. Biomaterials 22 (2001) 1335-1344
5. Clemens D.L., Lee B.Y., and Horwitz M.A. The Mycobacterium tuberculosis phagosome in human macrophages is isolated from the host cell cytoplasm. Infect. Immun. 70 (2002) 5800-5807
6. Couvreur P., Kante B., Roland M., Guiot P., Bauduin P., and Speiser P. Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J. Pharm. Pharmacol. 31 (1979) 331-332
7. De Cock K.M., and Wilkinson D. Tuberculosis control in resource-poor countries: alternative approaches in the era of HIV. Lancet 346 (1995) 675-677
8. Donald P.R., Sirgel F.A., Venter A., Smit E., Parkin D.P., Van de Wai B.W., and Mitchison D.A. The early bactericidal activity of a low-clearance liposomal amikacin in pulmonary tuberculosis. J. Antimicrob. Chemother. 48 (2001) 877-880
9. Fawaz F., Guyot M., Lagueny A.M., and Devissageut J.Ph. Ciprofloxacin-loaded polyisobutylcyanoacrylate nanoparticles: preparation and characterization. Int. J. Pharm. 154 (1997) 191-203
10. Fawaz F., Bonini F., and Maugein J. Ciprofloxacin-loaded polyisobutylcyanoacrylate nanoparticles: pharmacokinetics and in vitro antimicrobial activity. Int. J. Pharm. 168 (1998) 255-259
11. Fresta M., Puglisi G., Giammona G., Cavallaro G., Micali N., and Furneri P.M. Pefloxacine mesilate- and ofloxacin-loaded polyethylcyanoacrylate nanoparticles: characterization of the colloidal drug carrier formulation. J. Pharm. Sci. 84 (1995) 895-902
12. Gelband H. Regimens of less than six months for treating tuberculosis. Cochrane Database Syst. Rev. 2 (2000) CD001362
13. Gelperina S.E., Khalansky A.S., Skidan I.N., Smirnova Z.S., Bobruskin A.I., Severin S.E., Turowski B., Zanella F.E., and Kreuter J. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol. Lett. 126 (2002) 131-141
14. Gosling R.D., Uiso L.O., Sam N.E., Bongard E., Kanduma E.G., Nyindo M., Morris R.W., and Gillespie S.H. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 168 (2003) 1342-1345
15. Gulyaev A.E., Gelperina S.E., Skidan I.N., Antropov A.S., Kivman G.Y., and Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 16 (1999) 1564-1569
16. Hall I.H., Schwab U.E., Ward E.S., and Ives T. Disposition and intracellular levels of moxifloxacin in human THP-1 monocytes in unstimulated and stimulated conditions. Int. J. Antimicrob. Agents 22 (2003) 579-587
17. Kreuter J. Physicochemical characterization of polyacrylic nanoparticles. Int. J. Pharm. 14 (1983) 43-58
18. Kreuter L., Alyautdin R.N., Kharkevich D.A., and Ivanov A.A. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 674 (1995) 171-174
19. Lherm C., Mueller R., Puisieux F., and Couvreur P. II. Cytotoxicity of cyanoacrylate nanoparticles with different alkyl chain length. Int. J. Pharm. 84 (1992) 13-22
20. Mitchison D.A. Drug resistance in tuberculosis. Eur. Respir. J. 25 (2005) 376-379
21. Mueller P., and Pieters J. Modulation of macrophage antimicrobial mechanisms by pathogenic mycobacteria. Immunobiology 211 (2006) 549-556
22. Myers J.P. New recommendations for the treatment of tuberculosis. Curr. Opin. Infect. Dis. 18 (2005) 133-140
23. Page-Clisson M.E., Pinto-Alphandary H., Ourevitch M., Andremont A., and Couvreur P. Development of ciprofloxacin-loaded nanoparticles: physicochemical study of the drug carrier. J. Control. Release 56 (1998) 23-32
24. Pereverzeva E., Treschalin I., Bodyagin D., Maksimenko O., Langer K., Dreis S., Asmussen B., Kreuter J., and Gelperina S. Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: focus on cardio- and testicular toxicity. Int. J. Pharm. 337 (2007) 346-356
25. Pinto-Alphandary H., Andremont A., and Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int. J. Antimicrob. Agents 13 (2000) 155-168
26. Sharma A., Pandey R., Sharma S., and Khuller G.K. Chemotherapeutic efficacy of poly (dl-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int. J. Antimicrob. Agents 24 (2004) 599-604
27. Steiniger S.C., Kreuter L., Khalansky A.S., Skidan I.N., Bobruskin A.I., Smirnova Z.S., Severin S.E., Uhl R., Kock M., Geiger K.D., and Gelperina S.E. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer 109 (2004) 759-767
28. Vauthier C., Dubernet C., Fattal E., Pinto-Alphandary H., and Couvreur P. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv. Drug Deliv. Rev. 55 (2003) 519-548